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Abstract
Hematopoietic stem cell transplant (HCT) recipients have a substantial risk of developing 
secondary solid cancers, particularly beyond 5 years after HCT and without reaching a plateau 
overtime. A working group was established through the Center for International Blood and 
Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with 
the goal to facilitate implementation of cancer screening appropriate to HCT recipients. The 
working group reviewed guidelines and methods for cancer screening applicable to the general 
population and reviewed the incidence and risk factors for secondary cancers after HCT. A 
consensus approach was used to establish recommendations for individual secondary cancers. The 
most common sites include oral cavity, skin, breast and thyroid. Risks of cancers are increased 
after HCT compared with the general population in skin, thyroid, oral cavity, esophagus, liver, 
nervous system, bone and connective tissues. Myeloablative TBI, young age at HCT, chronic 
GVHD and prolonged immunosuppressive treatment beyond 24 months were well-documented 
risk factors for many types of secondary cancers. All HCT recipients should be advised of the 
risks of secondary cancers annually and encouraged to undergo recommended screening based on 
their predisposition. Here we propose guidelines to help clinicians in providing screening and 
preventive care for secondary cancers among HCT recipients.
INTRODUCTION
Advances in hematopoietic cell transplantation (HCT) and supportive care measures have 
led to substantial improvements in long-term survival for HCT recipients.1 Transplant 
survivors are at considerable risk for developing significant late effects, and general 
recommendations regarding the multi-faceted approach required in their evaluation and 
treatment have been recently published.2 One particular challenge faced in the post-HCT 
setting is the risk of development of secondary malignancies. There is an increased risk of 
secondary malignancies following both autologous and allogeneic HCT, which may be 
further impacted by pretransplant therapies. Secondary malignancies can be grouped into 
post-transplant lymphoproliferative diseases, leukemia or myelodysplasia and solid cancers. 
The incidence of secondary solid malignancies can continue to rise over time and studies 
with follow-up to 20 years have not shown a plateau in their occurence.3–5
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Several organizations (for example, National Comprehensive Cancer Network (NCCN), 
American Cancer Society (ACS), United States Preventative Services Task Force) have 
developed standardized cancer screening methods that are currently implemented as part of a 
routine general health evaluation for certain malignancies in the general population, but 
application of these guidelines to HCT recipients have not been reviewed. In acknowledging 
the increased risk of secondary solid cancers among HCT recipients, a working group was 
established through the Center for International Blood and Marrow Transplant Research 
Late Effects and Quality of Life Working Committee and the European Group for Blood and 
Marrow Transplantation Complications and Quality of Life Working Party with the goal to 
facilitate implementation of cancer screening appropriate to HCT recipients. As a clinical 
output of this working group’s effort, we offer consensus-based recommendations applicable 
for screening and prevention of individual secondary solid cancers among HCT recipients.
METHODS
The goals of this document were to provide an expert review of existing, evidence-based, 
cancer screening guidelines applicable to the general population and adopt them to the post-
HCT setting. In order to integrate the incidence and risk factors of individual secondary 
cancers after HCT, an incidence rate and a standardized incidence ratio (SIR) (the ratio of 
observed cancer cases in a HCT cohort to expected cancer cases in the general population of 
similar age and gender) were summarized from existing literatures (Table 1) and reported 
risk factors for secondary cancer among HCT recipients were reviewed (Table 2). Cancer 
screening guidelines for the general population were primarily based on those established by 
ACS or NCCN, unless otherwise specified (Table 3). Details of screening guidelines and 
methods in the general population are summarized in the Supplementary Appendix. Adult 
and pediatric HCT recipients were considered in the development of these guidelines.
Skin cancer
Overview—There are three main types of skin cancer, including basal cell carcinoma 
(BCC), squamous cell carcinoma (SCC) and melanoma. Age-standardized incidence rates of 
melanoma in men and women were 3.3 and 2.8, respectively, per 100 000 person-years 
worldwide in 2012 (Figure 1).6 Age-standardized incidence rates of other skin cancers have 
not been reported. Incidence varies 100-fold between countries and ethnicities and is the 
highest in Caucasians. BCC and SCC are the most common and have better prognosis than 
other skin cancers in the general population. Actinic keratoses have been considered as 
direct precursors of both BCC and SCC, and the annual rate of transformation is estimated 
as 0.03–20%.7 Exposure to UV radiation is a well-known risk factor for melanoma and non-
melanoma skin cancers.8,9 The risk of developing skin cancers is incredibly high after solid 
organ transplantation owing to the chronic use of potent immunosuppression.10
Incidence and risk factors after transplantation—The reported incidence rates of 
skin cancers after HCT were 105 per 100 000 person-years for BCC, 76 for SCC and 18–76 
for melanoma.3,5,11,12 Reports describing skin cancer following HCT are dominated by case 
reports, but at least five large studies have reported an increased incidence of melanoma after 
allogeneic HCT compared with the general population (SIR 1.4–8.3).3,5,11–13 The risk of 
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developing melanoma was also increased compared with the general population after HCT 
with reduced-intensity conditioning (RIC) regimens (SIR 3.04 for leukemia or 
myelodysplastic syndrome patients and SIR 3.52 for lymphoma patients).13 An Asian study 
reported an increased incidence of skin cancers without distinguishing cancer subtypes after 
allogeneic HCT (SIR 7.2).14 One study reported that the cumulative incidences of BCC and 
SCC were 6.5% and 3.4% at 20 years after allogeneic HCT in a predominantly Caucasian 
cohort.15 Although it is rare, merkel cell carcinoma can occur after HCT,16 which is fatal in 
approximately one-third of patients and requires immediate treatment. Chronic GVHD 
(cGVHD), younger age at HCT and myeloablative TBI (that is, single doses ⩾ 10 Gy or 
fractionated doses ⩾ 13 Gy) are consistently reported risk factors for secondary skin cancer 
(Table 2).4,5,11,14,15,17 Voriconazole might increase the risk of skin cancer in organ 
transplant recipients, including HCT.18 The risk of skin cancer for patients who had 
allogeneic HCT for non-malignant disease remains undefined. A report restricted to 
autologous HCT demonstrated a SIR of 2.55 for melanoma, and multivariate analysis 
revealed age ⩾ 45 years, male patients and relapse following HCT as risk factors for 
melanoma development.19
Recommendation for transplant recipients—Given the considerations above, HCT 
recipients should maintain at least annual follow-up with their provider to incorporate skin 
cancer awareness and early disease recognition into routine late effects management. 
Photoprotection should be counseled to all HCT recipients as it can reduce the risk of skin 
cancer.20–22 Physical examination is the primary method for skin cancer screening. 
Heightened awareness is warranted for patients who received myeloablative TBI, those who 
had HCT at ages < 18 years, those with prior or concurrent GVHD of any form and those 
who had HCT for hereditary disorders, such as Fanconi anemia. Suspicious lesions should 
be addressed promptly, with management complying with standard practices.23
Thyroid cancer
Overview—Thyroid cancer is the most common endocrine cancer. Age-standardized 
incidence rates in men and women were 1.9 and 6.1, respectively, per 100 000 person-years 
worldwide in 2012 (Figure 1).6 The incidence of thyroid cancer has steadily risen over the 
past decades with no change in mortality rate (0.5 deaths per 100 000 person-years), which 
has largely been attributed to earlier detection.24 The incidence in women is approximately 
three times that in men and the median age at diagnosis is 50 years. Radiation and exposure 
to radioactive iodine isotopes are known risk factors for the development of thyroid cancer, 
though the majority of well-differentiated thyroid cancers (that is, papillary and follicular 
thyroid cancer) are unrelated to radiation exposure.
Incidence and risk factors after transplantation—Results have been conflicting in 
studies investigating the incidence of secondary thyroid cancer after HCT. Although some 
have found an increased incidence of thyroid cancers (SIR 5.8–6.5),5,11 others have not 
found any difference.12,25 In an attempt to better characterize the risk of secondary thyroid 
cancer, the European Group for Blood and Marrow Transplantation Late Effect Working 
Party reviewed data on 68 936 patients undergoing HCT between 1985 and 2003.26 They 
found an increased risk of secondary thyroid cancers when compared with the general 
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population, with a SIR of 3.26. Multivariate analysis revealed that age ⩽ 20 years at HCT 
was the strongest risk factor for secondary thyroid cancer (relative risk (RR) 24.6 for age 0–
10 years; RR 4.80 for age 11–20 years). Other risk factors were irradiation history (RR 
3.44), female gender (RR 2.79) and history of cGVHD (RR 2.94). The median interval 
between HCT and secondary thyroid cancer was 8.5 years.
Recommendations for transplant recipients—Physical examination (neck palpation) 
at least once a year remains the cornerstone of thyroid cancer screening. There is no 
evidence for routine imaging (for example, thyroid ultrasound) in screening. Heightened 
awareness is warranted for pediatric long-term survivors, female patients, TBI recipients and 
patients with cGVHD.
Oropharyngeal cancer
Overview—Age-standardized incidence rates of oropharyngeal cancer in men and women 
were 5.5 and 2.5, respectively, per 100 000 person-years worldwide in 2012 (Figure 1).6 
Oral squamous cell cancer (SCC) is the most common type and the major risk factors in the 
general population are tobacco and alcohol use.27 Human papilloma virus (HPV) and other 
viruses have also been implicated in the pathogenesis.28 Other reported risk factors are low 
socioeconomic status, dietary, tylosis, poor oral hygiene, use of chewing tobacco, betel nut 
chewing, occupational exposure, radiation and genetic predispositions.
Incidence and risk factors after transplantation—Among secondary cancers after 
HCT, oropharyngeal cancer is the most frequent (Table 1). The incidence rate of 
oropharyngeal cancer after HCT ranged from 32 to 92 per 100 000 person-years with a 7–
16-fold higher risk than the general population.3,5,11,14 The risk of oropharyngeal cancers 
was also elevated after HCT with RIC regimens (SIR 46.7).13 The risk of oral SCC is 
particularly high in patients with cGVHD receiving long-term immunosuppressive therapy ⩾ 
24 months.4,5,11,13–15,29–31 There was an association between oral cancer and male 
gender.5,11 In addition to cGVHD, conditioning regimens with limited field irradiation was 
associated with an increased risk of SCC of the oral cavity (RR = 4.7).5,11 A pediatric study 
showed an increased incidence of pharyngeal cancer after autologous HCT,32 whereas an 
adult study did not report oropharyngeal cancer after autologous HCT.33 Patients with 
hereditary disorders such as Fanconi anemia are at a significantly increased risk of 
oropharyngeal cancer. In immunocompromised patients, oncogenic viruses such as HPV 
may contribute to oropharyngeal SCC.34
Recommendation for transplant recipients—We recommend that all HCT recipients 
should be informed about the risks and symptoms of oropharyngeal cancer. Evaluation for 
premalignant lesions or oral cancer by a dentist or an oral surgeon is recommended 
annualy.2 Alternatively, primary care providers can include careful oral examination as part 
of an annual physical exam. Screening every 6 months may be considered for patients at 
high risk for developing oropharyngeal cancer (for example, cGVHD; Table 2). No 
definitive preventive interventions are recommended beyond general lifestyle counseling (for 
example, smoking cessation). Children who received radiation-containing treatment at a 
young age may require particular attention to screening for oropharyngeal cancer.
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Overview—Age-standardized incidence rates of esophageal cancer in men and women 
were 9.0 and 3.1, respectively, per 100 000 person-years worldwide in 2012 (Figure 1).6 
Adenocarcinoma is the most common subtype in countries where smoking rate is low, and 
SCC is the most common subtype in countries where smoking rate is high. Reported risk 
factors are tobacco use, alcohol use, low socioeconomic status, dietary, other esophageal 
diseases, previous head and neck cancer, bisphosphonate use, occupational exposure, 
radiation and genetic predispositions. Barrett’s esophagus is the major risk factor for 
esophageal adenocarcinoma in the general population. Factors known to increase the risk for 
Barrett’s esophagus include White ethnicity, older age, obesity and longstanding 
gastroesophageal reflux disease symptoms.35
Incidence and risk factors after transplantation—The incident rate of esophageal 
cancer after HCT ranges from 4 to 59 per 100 000 person-years and the SIR compared with 
the general population is 8.5–11-fold.3,5,14 The risk of secondary esophageal cancer was 
increased in patients with persistent cGVHD and those receiving long-term 
immunosuppressive therapy ⩾ 24 months.4,14 In particular, extensive-type cGVHD was a 
risk factor for esophageal cancer (RR = 5.3). Information is limited in the pediatric 
population. An adult study did not show an increased incidence of esophageal cancer after 
autologous HCT.33
Recommendation for transplant recipients—HCT recipients should be informed 
about the risks and symptoms of secondary esophageal cancer. Patients who have persistent 
gastroesophageal reflux disease symptoms or dysphagia should be evaluated by upper 
gastrointestinal (GI) endoscopy. Endoscopic screening can be considered in patients 
receiving prolonged immunosuppressive treatment ⩾ 24 months for cGVHD, especially if 
symptoms such as dysphagia and persistent heartburn are present. Barium swallow is 
inexpensive and could be used for screening, but its sensitivity is unknown.36
Gastric cancer
Overview—Gastric cancer was the fifth most common cancer worldwide in 2012 and age-
standardized incidence rates of gastric cancer in men and women were 17.4 and 7.5, 
respectively, per 100 000 person-years (Figure 1).6 Almost three quarters of the new cases 
occurred in Asia. Incidence varies 10-fold between countries, with the highest incidence in 
East Asia and central and Eastern Europe. Incidence rates are low in Africa and in North 
America. Helicobacter pylori infection is a well-established carcinogen for gastric cancer 
and is found in approximately 75% of all cases of gastric cancer.37
Incidence and risk factors after transplantation—Although GI tract cancers are 
among the most common cancers worldwide, current data in HCT survivors have not 
necessarily indicated an increased risk of secondary gastric cancer relative to the general 
population.3,11,12,38–41 In the largest study of long-term HCT survivors, no gastric cancers 
were reported.5 Although cGVHD has been linked to secondary SCC, cGVHD does not 
appear to be associated with gastric cancer. Given the long latency of GI cancers, studies 
with longer-term follow-up are needed to clarify the risk of GI cancers after HCT. Of note, 
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most secondary cancer studies have included patients from regions with a low prevalence of 
gastric cancer.
Recommendation for transplant recipients—There are currently no data indicating 
an increased risk of secondary gastric cancers in HCT recipients. Routine screening for 
gastric cancer in HCT recipients is not recommended, but following local screening 
recommendations based on geographic location and associated predisposition may be 
considered.
Colorectal cancer
Overview—Colorectal cancer represents almost 10% of the global cancer incidence burden 
in 2012 and is the third most common cancer in men and the second most common cancer in 
women. Age-standardized incidence rates in men and women were 20.6 and 14.3, 
respectively, per 100 000 person-years worldwide in 2012 (Figure 1).6 Incidence varies 10-
fold between countries in both genders and rates tend to be low in many African countries.
Incidence and risk factors after transplantation—Limited data in the post-HCT 
setting do not indicate a greatly increased risk of secondary colorectal cancers relative to the 
general population.3,11,12,38–41 In the largest study of long-term HCT survivors, there were 
only two cases of colon cancer (observed/expected (O/E), 0.52; 95% confidence interval 
(CI), 0.06–1.89) and four cases of rectal cancer (O/E, 1.67; 95% CI, 0.46–4.29) described 
among 28 874 patients.5 Secondary GI cancers were similarly infrequent in a recent cohort 
of 4269 long-term survivors of HCT with RIC regimens (1 small intestinal cancer, 3 colon 
cancers, and 2 rectal cancers).13 A more recent study that included 17 545 HCT recipients, 
in contrast to prior reports, did find an increased risk (SIR 1.9) of colon cancer.14
Recommendation for transplant recipients—The data indicating an increased risk of 
secondary colorectal cancers in HCT recipients is limited, but has been reported.14 It is 
recommended that HCT recipients undergo screening for secondary colorectal cancers 
according to the current general population guidelines (Table 3). This would include 
consideration of annual stool guaiac testing, flexible sigmoidoscopy every 5 years or 
colonoscopy every 10 years, with earlier and more frequent screening in high-risk patients.
Liver cancer
Overview—The annual incidence of hepatocellular carcinoma (HCC) is rising worldwide. 
Age-standardized incidence rates in men and women were 15.3 and 5.4, respectively, per 
100 000 person-years worldwide in 2012 (Figure 1).6 A history of hepatitis B, hepatitis C, 
chronic active hepatitis and cirrhosis are potential risk factors for the development of HCC.
Incidence and risk factors after transplantation—An increased incidence of liver 
cancer in long-term survivors of both autologous and myeloablative allogeneic HCT has 
been reported (6–28-fold increased risk compared with the general population) by 
some5,11,25 but not all studies (Table 1).12 Similarly, a trend towards increased incidence of 
liver cancer is also noted in recipients of allogeneic HCT with RIC regimens (SIR, 5.96; 
95% CI, 0.72–21.54).13 Risk factors of liver cancer in HCT survivors include younger age 
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(< 34 years) at HCT (SIR, 200; 95% CI, 18.9–573.2), history of chronic hepatitis C 
infection, liver cirrhosis and TBI-based conditioning (SIR, 20.0; 95% CI, 1.9–57.3)(Table 
2).42 No data indicate that GVHD increases the risk of liver cancer in allogeneic HCT 
survivors. An additional consideration in the post-HCT population is the potential for iron 
overload from prior transfusions.43,44 Iron overload can contribute to the development of 
chronic liver disease and/or subsequent HCC in cases of both hereditary45 and acquired iron 
overload syndromes,46 but further studies are needed to determine whether there would be 
similar implications of iron overload in the post-HCT setting.
Recommendation for transplant recipients—General population guidelines can be 
followed for screening for HCC in HCT survivors (screening liver ultrasound every 6 
months in patients at increased risk for developing HCC, as defined in AASLD 
guidelines).54
Lung cancer
Overview—Lung cancer is the most frequent cancer worldwide and is the leading cause of 
cancer death in men and in women. Age-standardized incidence rates in men and women 
were 34.2 and 13.6, respectively, per 100 000 person-years worldwide in 2012 (Figure 1).6 
Incidence varies 80-fold between countries, with the highest incidence in North America, 
Europe and East Asia and relatively low incidence in many African countries. The two main 
classes of lung cancer are small cell lung carcinoma (SCLC) and non-SCLC. Non-SCLC is 
further subdivided into adenocarcinoma, squamous cell carcinoma and large cell carcinoma. 
SCLC is strongly associated with tobacco use in the general population.
Incidence and risk factors after transplantation—Reported SIRs for secondary lung 
cancer in HCT survivors compared with the general population vary among large studies 
from 0.7 to 2.6.3,5,11–14 A recent study evaluated the incidence and risk factors for solid 
cancers after HCT using high-dose BU and CY conditioning in 4318 recipients of first 
allogeneic HCT. In this study, lung cancer was the most common site (n = 11, including 9 
with non-SCLC, among 66 patients with all solid cancers).3 Median age at HCT for these 11 
patients was 48 (range, 24–58) years, and lung cancer occurred at a median of 4.5 years after 
HCT. The association of radiation (for example, TBI) and lung cancer risk in HCT survivors 
is not well established, especially when lung shielding is applied. Limited data in the setting 
of radiation used for the treatment of Hodgkin lymphoma, however, suggest an increase in 
the risk of lung cancer following radiation therapy.47,48 Tobacco use prior to HCT was a 
strong risk factor for developing secondary lung cancer (RR = 11.6, P = 0.02).3 In other 
large studies, however, overall SIRs of developing secondary lung cancers were not 
significantly elevated compared with the general population.5,11–14
Recommendation for transplant recipients—Patients preparing to undergo HCT who 
are current smokers should be counseled to quit immediately to avoid the risks of secondary 
lung cancers and other adverse post-HCT health effects. Past or current smokers who are 
HCT survivors should be counseled about the risks of secondary lung cancer. Assessment of 
tobacco use, counseling against smoking and smoking cessation guidance for current 
smokers should be routinely included as part of post-transplant assessment.2 Screening with 
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low-dose computed tomography may be offered to high-risk smokers and former smokers 
according to general population guidelines.49
Breast cancer
Overview—Breast cancer is the most frequently diagnosed and the leading cause of cancer 
death in women worldwide.50,51 An age-standardized incidence rate of breast cancer was 
43.3 per 100 000 person-years worldwide in 2012 (Figure 1).6 Introduction of screening 
programs has reduced breast cancer-related mortality by 20–48%.52,53
Incidence and risk factors after transplantation—Overall incidence of breast cancer 
is not increased among HCT survivors as compared with the general population (Table 1). 
Among HCT survivors, however, patients who had HCT at a younger age have an increased 
risk of developing breast cancer, with the highest incidence in young females < 18 years at 
HCT. The risk remains elevated for subsequent age groups.12,32,54 The incidence of breast 
cancer was increased markedly from 0.8% at 10 years to 4.6% at 20 years, reaching 11% at 
25 years after HCT.54 Similar results have been observed in other studies.5,11,32 The use of 
TBI-based conditioning regimens has been associated with an increased risk of breast cancer 
after allogeneic HCT.5,54 The effect of TBI seems to be greater in children irradiated before 
10 years of age with a 55-fold increase in the risk of developing solid cancers, including 
breast cancer. The risk remains elevated at 4–6-fold among recipients irradiated between 10 
and 19 years and 20 and 29 years. The incidence of breast cancer was increased among 
patients > 50 years of age who received BU–CY conditioning regimen,3 but the incidence 
was not increased among patients of similar age in another study.14 Other studies have 
reported an increased risk of breast cancer associated with antithymocyte globulin5 or 
growth factors.3 One study, in which many patients received radiation therapy before HCT 
or as part of conditioning, showed a higher risk of developing breast cancer in pediatric 
patients after autologous HCT.32 In contrast, none of 1482 adult patients in another large 
cohort of autologous HCT recipients developed breast cancer.33
Recommendation for transplant recipients—Breast awareness should be emphasized 
for all long-term survivors after HCT, with prompt reporting of any new breast symptoms 
(for example, new nodules) to a health-care professional. Mammograms and clinical breast 
exam beginning at age 40 years and occurring every 1–2 years are recommended for all 
HCT recipients. For patients who received chest radiation or TBI, special consideration 
should be given for annual clinical breast exam, mammography and breast magnetic 
resonance imaging beginning at age 25 years or 8 years after radiation or TBI, whichever 
occurs later, but no later than 40 years of age.2 Screening at an earlier age may also be 
considered in women at high risk for breast cancer (for example, known BRCA mutations) 
and should follow general population screening guidelines. Breast ultrasound may be 
considered in addition to mammography for high-risk women, but additional benefits over 
magnetic resonance imaging are undetermined.55
Cervical and endometrial cancer
Overview—Age-standardized incidence rate of cervical cancer was 14.0 per 100 000 
person-years worldwide in 2012 (Figure 1).6 The incidence and mortality rate of cervical 
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cancer have declined since the introduction of the Papanicolaou (Pap) test. More than 80% 
cases are SCC and 10–20% are adenocarcinomas. Cervical cancers present with no 
symptoms in early stages but progresses to abnormal vaginal bleeding, pelvic pain or pain 
during intercourse in advanced stages. As HPV of high-risk subtypes such as HPV16 and 
HPV18 causes > 90% of cases, routine HPV vaccination is recommended for females aged 
9–26 years.56,57 The Centers for Disease Control and Prevention recommends HPV 
vaccination for girls and boys at age 11 or 12 years. Age-standardized incidence rate of 
endometrial cancer was 8.2 per 100 000 person-years worldwide in 2012 (Figure 1).6 
Endometrial cancers typically occur after menopause, and the first symptom is often vaginal 
bleeding. Obesity and excessive estrogen exposure are known risk factors.58 It often 
develops from endometrial hyperplasia and 80% of cases are endometrioid carcinoma.
Incidence and risk factors after transplantation—The reported incidence rates of 
cervical and endometrial cancers occurring after HCT are 2–67 and 2–7 per 100 000 person-
years.3,5,11,14 Several studies have shown that the overall incidence rates of these cancers did 
not differ from the general population,3,5,11,14 but one study reported a 13-fold increased 
risk of cervical cancer compared with the general population (Table 1).25 Age > 34 years 
and systemically treated cGVHD for > 3 years were associated with an increased risk of 
cervical cancer (Table 2).25,59 HPV-related cervical dysplasia occurred in more than one-
third of long-term survivors after allogeneic HCT, and most cases had high-risk HPV 
subtypes 16 and 18.59 Risk factors for endometrial cancer after HCT have not been studied. 
Information on cervical or endometrial cancer after autologous HCT or in the pediatric 
population are limited, although some studies have included adult survivors of HCT during 
childhood.32
Recommendation for transplant recipients—The screening and preventive practice 
guidelines for HCT recipients recommend annual pelvic exam for all female HCT survivors, 
ideally to begin in the year following transplant, as age appropriate.2,60 Screening methods 
recommended for the general population by expert societies apply to HCT recipients as 
well.61 Although the efficacy of HPV vaccination in HCT recipient remains to be 
determined, the Centers for Disease Control and Prevention has recommended vaccination 
in those who are immunocompromised.57,62 Three doses of HPV vaccination starting at 1 
year after allogeneic HCT are provided in some transplant centers for males and females 
aged 9–26 years. Although there are no clear contraindications to vaccination, studies 
demonstrating its effectiveness in the post-transplant setting are lacking and clinical studies 
are needed to evaluate the benefit in this subpopulation. Information about the risks and 
symptoms of endometrial cancers (any unexpected bleeding or spotting) should be provided 
to female HCT recipients at the time of menopause. Combination of estrogen and 
progestogens should be used for HCT recipients who need hormone-replacement 
therapy,63,64 as estrogen alone increases risk of endometrial cancer in the general 
population.65,66
Ovarian cancer
Overview—Ovarian cancer is the second most common gynecological cancer in developed 
countries. Age-standardized incidence rate of ovarian cancer was 6.1 per 100 000 person-
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years worldwide in 2012 (Figure 1).6 The fatality rate of ovarian cancer is higher than other 
cancers of the female reproductive organs. Ovarian carcinomas are the most common type 
and nulliparous women are more frequently affected than those with suppressed ovulation 
typically by pregnancy or oral contraceptives.
Incidence and risk factors after transplantation—Few studies have reported on the 
incidence of ovarian cancer after HCT. In long-term Asian survivors of allogeneic HCT 
compared with the general population, the incidence of ovarian cancer does not appear to be 
increased (SIR 0.8; 95% CI 0.2–2.4%; Table 1).14 No specific risk factors predisposing to 
secondary ovarian cancer among HCT recipients are known.
Screening recommendations for transplant recipients—Routine ovarian cancer 
screening in average-risk transplant survivors is not recommended. Evaluation should 
instead focus on early detection in symptomatic patients. Such evaluation includes physical 
exam, transvaginal ultrasound and serum CA-125 levels.67
Prostate cancer
Overview—Prostate cancer is most frequent in men > 65 years but rarely reported as a 
primary cause of death.68 Age-standardized incidence rate was 31.1 per 100 000 person-
years worldwide in 2012 (Figure 1).6 In the general population, risk factors for prostate 
cancer are family history, African American ethnicity, older age and abnormal digital rectal 
examination.23
Incidence and risk factors after transplantation—The incidence rate of prostate 
cancer after HCT is 4–10 per 100 000 patient-years, and the risk has not exceeded the risk in 
the general population.3,5,11,12,14,38,69 No specific risk factors predisposing to secondary 
prostate cancer among HCT recipients are known.
Recommendation for transplant recipients—HCT survivors should follow guidelines 
for the general population. For prostate cancer, after an informed decision-making process 
for asymptomatic men aged > 50 years with life expectancy of at least 10 years, or for those 
considered to be at higher risk, consideration should be made for routine digital rectal 
examination with or without prostate-specific antigen.23,70–72
Testicular cancer
Overview—Testicular cancer usually presents between 20 and 30 years of age and 
represents about 1% of male malignant tumors.73 Age-standardized incidence rate was 1.5 
per 100 000 person-years worldwide in 2012 (Figure 1).6 Risk factors for testicular cancer 
include cryptorchidism/hypospadias, a personal or family history of testicular cancer, 
infertility, tobacco use, increased height or weight, HIV infection, Caucasian or Hispanic 
ethnicity and exposure to organochlorine compounds.73–82
Incidence and risk factors after transplantation—The incidence rate of testicular 
cancer after HCT is 4–5 per 100 000 patient-years, and the risk after HCT does not seem to 
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exceed the risk in the general population.3,5,11,12,14,38,69 No specific risk factors 
predisposing to secondary testicular cancer among HCT recipients are known.
Recommendation for transplant recipients—Screening recommendations for 
testicular cancer among HCT recipients should mirror screening recommendations in the 
general population, including performance of a testicular exam as part of a routine annual 
physical exam.
Other secondary solid cancers
In addition to screening for cancers that the general population is also at risk for, it is notable 
that patients with history of cancer or who are post-transplant are at higher risk for cancers 
where there are no routine screening recommendations. These include central nervous 
system tumors and sarcomas (Table 1).3 Although there is no evidence to suggest clear 
recommendations for screening, providers should maintain vigilance and have a high level 
of suspicion in patients who present with relevant symptoms. Central nervous system tumors 
may be of particular concern in those who have previously undergone central nervous 
system irradiation as part of prior therapy or have received TBI.83
Additional considerations
The incidence of secondary solid cancers did not differ according to donor type or HLA 
matching in many previous studies.3–5,11,12,14,15,54 As previous studies included few cord 
blood or haploidentical transplantation, further studies are warranted to characterize 
outcomes after the use of these new graft sources. One recent study found a similar risk of 
secondary cancers between RIC and myeloablative conditioning for leukemia or 
myelodysplastic syndrome patients and a lower risk of secondary cancers after RIC than 
after myeloablative conditioning for lymphoma patients.13 Compared with allogeneic HCT, 
data of secondary solid cancers after autologous HCT are relatively lacking partly because 
recurrent malignancy occurs frequently after autologous HCT, precluding long-term follow-
up to investigate secondary cancers. Some studies found different risks of secondary cancers 
according to diseases indicated for HCT or recipient genders. The risk of secondary cancers 
was increased in patients with acute leukemia or chronic myeloid leukemia but not in those 
with lymphoma or severe aplastic anemia.25 The risk of skin BCC was higher in patients 
with hematological malignancies than those with benign diseases.15 The risk of SCC in the 
skin and mouth was higher in male recipients than in female recipients.5,11 The risks of 
thyroid cancer and melanoma were higher in female recipients than in male recipients.5,26
Although the consensus recommendations and this manuscript provide a general overview of 
risks related to development of secondary solid cancers, a few caveats have to be considered. 
First, incidence of cancers may differ by race and ethnicity and the practice of cancer 
screening may differ among countries. As available literature is dominated by studies of 
Western populations with an overrepresentation of Caucasians, our recommendations would 
require careful application in other races, ethnicities and regions (for example, risks of 
gastric cancer in Asian populations). Second, reported incidences of secondary malignancies 
after HCT rely largely on registry data, which may underestimate the true incidence as 
transplant centers may not have information on long-term HCT survivors. Hence, we would 
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emphasize that transplant centers keep in touch with long-term survivors and report events in 
order to accurately estimate the incidence of secondary cancers. Finally, establishing the 
appropriate time after transplant to initiate screening for secondary malignancies is not clear, 
especially given the long latency of certain solid cancers and the steady rise in incidence, 
which is especially important when considering secondary cancer screening in those who 
underwent HCT as children. This is demonstrated by a Nordic study consisting of 47 697 
patients with childhood cancers followed up to age 79 years.84 The cumulative risk of a 
secondary cancer increased substantially at the age of 60–80 years, with a predominance of 
cancers of the breast, GI, respiratory or genitourinary organs in patients ⩾ 60 years, which 
was a different distribution compared with secondary cancers seen in younger patients. 
Certainly, children who undergo HCT will continue to be at increased risk for development 
of secondary solid cancers over the course of their lifetime, but adopting standard practice 
guidelines that are applicable in the general adult population may be neither feasible nor 
reliable in a younger population. Hence, for children it will be even more imperative to rely 
on clinical signs/symptoms that would prompt early initiation of screening as opposed to 
only that which would be initiated solely based on age.
CONCLUSION
In conclusion, we provide our consensus recommendations for secondary solid cancer 
screening in Table 3. As risks of cancers in the skin, thyroid, oral cavity, esophagus, liver, 
brain/nervous system, bone and connective tissues are increased after HCT compared with 
the general population, heightened awareness is warranted for these sites. These 
recommendations will inform future iterations of screening and preventive practice 
guidelines for HCT survivors.
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Age-standardized cancer incidence rate in the general population. Data were based on 
Cancer Incidence in Five Continents Time Trends in 2012.85
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Table 2
Reported risk factors for individual secondary cancers among HCT population
Site Risk factor
Skin Chronic GVHD19
SCC Acute GVHD,20 chronic GVHD,4,5,20 male,5 age < 18
years at transplantation20
BCC Age < 18 years at transplantation,20 myeloablative
TBI conditioning,20,22 white,20,22 chronic GVHD,19,20
attained age22
Melanoma Myeloablative TBI conditioning,5,16 T-cell depletion,5
female5
Thyroid Radiation conditioning,5,32 female,32 age ⩽ 20 years
at transplantation,32 chronic GVHD32
Oral Persistent chronic GVHD,4,5,16,18–20,36–38 cumulative
duration of immunosuppressive therapy, including
prophylaxis > 24 months,4 history of localized field
irradiation,5,16 ages < 10 y.o. at the time of transplant,5
male gender5,16
Esophagus Persistent chronic GVHD,4,19 prolonged
immunosuppressive therapy > 24 months4
Stomach None reported
Colorectal None reported
Liver TBI-based conditioning, younger age (< 34 years) at
HCT, liver cirrhosis, chronic hepatitis C infection54
Lung Tobacco use prior to transplantation3
Breast History of myeloablative TBI or radiation treatment,5,74
longer time since HCT,5,16,39,74 age < 18 years at
HCT,17,39,74 use of growth factors,3 antithymocyte
globulin5
Cervix Chronic GVHD with systemic immunosuppressive





Brain/CNS None reported, prior history of CNS irradiation may
increase risk.115
Sarcoma None reported
Abbreviations: BCC = basal cell carcinoma; CNS = central nervous system; HCT = hematopoietic stem cell transplant; SCC = squamous cell 
carcinoma.
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